Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.
Type:
Grant
Filed:
December 19, 2017
Date of Patent:
September 15, 2020
Assignee:
MORPHOSYS AG
Inventors:
Stefan Haertle, Christian Frisch, Achim Knappik
Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
May 12, 2020
Assignee:
MORPHOSYS AG
Inventors:
Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
Type:
Grant
Filed:
February 26, 2019
Date of Patent:
April 28, 2020
Assignees:
MORPHOSYS AG, GALAPAGOS NV
Inventors:
Jan Dominik Haas, Jürgen Klattig, Nick Ernest Rene Vandeghinste
Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Type:
Grant
Filed:
May 25, 2016
Date of Patent:
April 14, 2020
Assignee:
MORPHOSYS AG
Inventors:
Jan Endell, Rainer Boxhammer, Mark Winderlich
Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Type:
Application
Filed:
June 17, 2019
Publication date:
January 23, 2020
Applicant:
MORPHOSYS AG
Inventors:
Stefan Steidl, Elisabeth THOMASSEN-WOLF
Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
Type:
Grant
Filed:
May 13, 2016
Date of Patent:
January 14, 2020
Assignee:
MORPHOSYS AG
Inventors:
Stéphane LeClair, Jan Endell, Stefan Härtle
Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Type:
Grant
Filed:
December 21, 2016
Date of Patent:
August 13, 2019
Assignee:
Morphosys AG
Inventors:
Stefan Steidl, Elisabeth Thomassen-Wolf
Abstract: The present disclosure is directed to a method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody in combination with thalidomide, lenalidomide, or pomalidomide.
Type:
Grant
Filed:
August 7, 2017
Date of Patent:
June 4, 2019
Assignee:
MORPHOSYS AG
Inventors:
Lisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
Abstract: The present disclosure relates to fusion proteins that are highly useful for the generation of virus-like particles for the display of membrane spanning proteins. Related embodiments, methods and uses are disclosed.
Type:
Grant
Filed:
June 9, 2015
Date of Patent:
April 30, 2019
Assignee:
MORPHOSYS AG
Inventors:
Sebastian Jaeger, Daniela Daubert, Kathrin Goetz
Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
Type:
Grant
Filed:
August 8, 2018
Date of Patent:
April 16, 2019
Assignees:
MORPHOSYS AG, GALAPAGOS NV
Inventors:
Jan Dominik Haas, Jürgen Klattig, Nick Ernest René Vandeghinste
Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
Type:
Application
Filed:
February 17, 2017
Publication date:
February 14, 2019
Applicants:
MORPHOSYS AG, GALAPAGOS NV
Inventors:
Jan Dominik HAAS, Jürgen KLATTIG, Nick Ernest René VANDEGHINSTE
Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
Abstract: This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.
Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
Type:
Application
Filed:
January 26, 2018
Publication date:
August 16, 2018
Applicant:
Morphosys Ag
Inventors:
Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl
Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
Type:
Grant
Filed:
December 16, 2015
Date of Patent:
June 26, 2018
Assignees:
MORPHOSYS AG, THE UNIVERSITY OF MELBOURNE
Inventors:
Stefan Steidl, John Allan Hamilton, Andrew David Cook
Abstract: This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.
Abstract: This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof.